ライフサイエンスコーパス: dementia

1 patients with Pick's disease (frontotemporal dementia).

2 risk for common neurological sequelae (e.g., dementia).

3 sed the treatment of MCI or mild to moderate dementia.

4 ), 9,776 (4.2%) patients were diagnosed with dementia.

5 including 374 cases with Alzheimer's disease dementia.

6 th risk of all-cause and Alzheimer's disease dementia.

7 psychotic and catatonic symptoms and severe dementia.

8 t who did not convert to Alzheimer's disease dementia.

9 rst-eye cataract surgery, 23,332 (5.1%) with dementia.

10 se (AD) that correlates with the severity of dementia.

11 diazepines were linked to increased risks of dementia.

12 Z-drugs at baseline were not associated with dementia.

13 g autism, schizophrenia, and fronto-temporal dementia.

14 symptoms specific to patients with Lewy body dementia.

15 et of Alzheimer's disease (AD) and all-cause dementia.

16 rtionately burdened by cognitive decline and dementia.

17 ain-behaviour relationships in patients with dementia.

18 (HAND), such as encephalitis and early-onset dementia.

19 on and protein aggregation in frontotemporal dementia.

20 ssing mealtime engagement toward people with dementia.

21 impairment (MCI) is the most common type of dementia.

22 re effective than others in lowering risk of dementia.

23 dividuals with either normal cognition or AD dementia.

24 tudes, skills, and behaviors for people with dementia.

25 Neighborhood LC-SES was not associated with dementia.

26 neurons during the onset and progression of dementia.

27 severely impact path integration systems in dementia.

28 otential to improve outcomes for people with dementia.

29 A history of depression is a risk factor for dementia.

30 pairment may be a modifiable risk factor for dementia.

31 be key to developing effective therapies for dementia.

32 isability-free survival or avoiding death or dementia.

33 roposed to explain the association of AF and dementia.

34 ssess mealtime engagement toward people with dementia.

35 tient with advanced CKD and mild to moderate dementia.

36 diovascular and cerebrovascular diseases and dementia.

37 also a risk factor for cognitive decline and dementia.

38 another two donors with LATE-NC did not have dementia.

39 lyze the association between body height and dementia.

40 o in capturing the pathogenesis of Alzheimer dementia.

41 omic dysfunction) in patients with Lewy body dementia.

42 s may be crucial to reduce late-life risk of dementia.

43 ife care is often inadequate for people with dementia.

44 rly signs of hypometabolism, associated with dementia.

45 , is elevated in subjects who progress to AD dementia.

46 a (bvFTD) is a frequent cause of early-onset dementia.

47 entially the most modifiable risk factor for dementia.

48 r pathogenic link between these two forms of dementia.

49 nto pharmacological treatment of humans with dementia.

50 D patients, omega-3 may delay progression to dementia.

51 essel disease, the leading cause of vascular dementia.

52 smooth muscle cell degeneration, stroke, and dementia.

53 ns implicated in structural brain changes in dementia.

54 in pathology including Alzheimer's and other dementias.

55 vated in those who progress to AD and non-AD dementias.

56 e linked with an enhanced risk of developing dementias.

57 vulnerability to Alzheimer's disease-related dementias.

58 al insights into the precursors of late-life dementias.

59 reas NfL was increased in both AD and non-AD dementias.

60 ing Kufor-Rakeb syndrome-a parkinsonism with dementia(1)-and early-onset Parkinson's disease(2).

61 rment (3.0 +/- 5.3%) and Alzheimer's disease dementia (2.9 +/- 5.7%), respectively, when compared to

62 years vs 60.3 [16.0] years; p <0.0001), had dementia (35 [28.7%] vs 34 [11.4%]; p <0.0001), hemipleg

63 80.0 billion [95% CI, $72.2-$86.1 billion]), dementias ($79.2 billion [95% CI, $67.6-$90.8 billion]),

64 nitive impairment, which often progresses to dementia, a major cause of morbidity and disability.

65 8 years [SD 1.3]), 1069 people progressed to dementia across all sites (incidence rate 24.9 cases per

66 e expression (GReX) of ZC3H12B and Alzheimer dementia (AD) (p value = 5.42 x 10(-13)), neurofibrillar

67 ntrols (HC) and individuals with Alzheimer's dementia (AD).

68 s associated with a higher risk of all-cause dementia [adjusted HR 1.59 (95% CI, 1.38-1.83); P < 0.00

69 developing all-cause or Alzheimer's disease dementia, adjusted hazard ratio (HR) 0.61 [95% confidenc

70 Dementia affects an estimated 2.4 to 5.5 million individ

71 the second most prevalent form of pre-senile dementia after Alzheimer's disease.

72 cognitive impairment and 71 with Alzheimer's dementia, age range 56-88 years), we investigated grey m

73 trophic Lateral Sclerosis and Frontotemporal Dementia (ALS/FTD).

74 Dementia (also known as major neurocognitive disorder) i

75 Normal aging, in the absence of dementia, also results in gradual cognitive decline and

76 ts did not have increased long-term risks of dementia, Alzheimer's disease, Parkinson's disease, moto

77 we examined the associations between LNB and dementia, Alzheimer's disease, Parkinson's disease, moto

78 We observed no long-term increased risks of dementia, Alzheimer's disease, Parkinson's disease, moto

79 nd infections with incident AD and all-cause dementia, among older adults (>=65 years at baseline).

80 a including Alzheimer's disease and vascular dementia, analyzing data from participants aged 40 years

81 Disease Neuroimaging Initiative (17 with AD dementia and 199 with mild cognitive impairment), includ

82 5-85 years with probable Alzheimer's disease dementia and a Mini Mental State Examination score >=15

83 sociated with the accelerated development of dementia and a more aggressive motor course.

84 nervous system characterizes frontotemporal dementia and ALS in many individuals with these neurodeg

85 somal dominant inheritance of frontotemporal dementia and amyotrophic lateral sclerosis and no mutati

86 Frontotemporal dementia and amyotrophic lateral sclerosis are clinicall

87 Mutations in several frontotemporal dementia and amyotrophic lateral sclerosis genes, includ

88 atherosclerosis and development of vascular dementia and cerebral small vessel disease but not betwe

89 d the incidence of dementia (or composite of dementia and cognitive impairment [3 trials]) on follow-

90 arkinson's disease, Parkinson's disease with dementia and dementia with Lewy bodies (DLB), are human

91 ted NGS dementia panel to 3241 patients with dementia and healthy aged controls; 13,152 variants were

92 current stroke, disability, quality of life, dementia and hospital care costs stratified by haematoma

93 ompared with the general population) of both dementia and its prodrome, mild cognitive impairment (MC

94 rt genes are observed in PD with and without dementia and Lewy body dementia, but these changes are a

95 ly higher 10-year risks of recurrent stroke, dementia and lower QALYs after lobar ICH highlight the n

96 enuated the effect of intensive treatment on dementia and MCI incidence.

97 (n = 12 with clinically probable Alzheimer's dementia and n = 14 with amyloid-positive mild cognitive

98 lth and disease including neurodegeneration, dementia and other brain phenotypes.

99 protein tau), which can cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-

100 ewy bodies (n = 12), mixed Alzheimer disease dementia and probable dementia with Lewy bodies (n = 1),

101 symptomatic drug treatment of frontotemporal dementia and progressive supranuclear palsy.

102 s remained after excluding incident cases of dementia and stroke during the follow-up, or further adj

103 nderlying mechanisms linking BP variation to dementia and stroke.

104 ndent interaction between the development of dementia and the incidence of CVD in several populations

105 care planning is acceptable for people with dementia and their carers and is associated with improve

106 ree other proteins encoded by frontotemporal dementia and/or amyotrophic lateral sclerosis genes (TBK

107 ar risk of negative experiences: people with dementia and/or delirium; people with difficulty communi

108 pletion to admission, histories of cancer or dementia, and admission for traumatic injury.

109 s to reduce or cope with refusals of care in dementia, and determine the evidence for these.

110 =65 years of age and free of documented CVD, dementia, and disability.

111 inical picture of parkinsonism and Lewy body dementia, and E46K creates more pathogenic fibrils in vi

112 asyn occur in Parkinson's disease, Lewy body dementia, and multiple system atrophy and animal disease

113 ltiple sclerosis, mild cognitive impairment, dementia, and Parkinson's disease, supporting the releva

114 tors (GPCRs) are targets in the treatment of dementia, and the arrestins are common to their signalin

115 r's disease may actually suffer from a mixed dementia, and therapeutics targeting only Alzheimer's di

116 erted to AD dementia, or converted to non-AD dementias, and in cognitively unimpaired participants.

117 The clinical syndromes of frontotemporal dementia are clinically and neuropathologically heteroge

118 Refusals of care in dementia are common and can create difficult situations

119 ries undergoing cataract surgery, those with dementia are more likely to have "complex" surgery" last

120 heimer's disease (AD) is a neurodegenerative dementia associated with deposition of amyloid plaques a

121 (AD) is the most common age-related form of dementia, associated with deposition of intracellular ne

122 dividuals aged 65 years or older and without dementia at baseline were selected from China, Cuba, the

123 ticipants with European ancestry and without dementia at enrollment.

124 Older persons without dementia at study enrollment (n = 1,010) had annual cogn

125 nerative disorders, including frontotemporal dementia (AUC=82.76-100% across cohorts), vascular demen

126 ia (AUC=82.76-100% across cohorts), vascular dementia (AUC=92.13%), progressive supranuclear palsy or

127 Individuals clinically classified as AD dementia but having negative Abeta PET scans show little

128 ognitive decline or with conversion rates to dementia but high salivary cortisol levels were associat

129 consequences including cognitive decline and dementia, but research on the link between smoking and b

130 n PD with and without dementia and Lewy body dementia, but these changes are attenuated or reversed a

131 The behavioural variant of frontotemporal dementia (bvFTD) is a frequent cause of early-onset deme

132 ession was used to estimate hazard ratios of dementia by LC-SES scores in race-specific models.

133 nish Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) study, who were followed from midlife (

134 D, the second most common form of pre-senile dementia, can also be caused by genetic mutations in oth

135 rkinson's disease proxy cases, 622 Lewy body dementia cases and 180 355 controls), we identified 1691

136 1691 Parkinson's disease cases, 81 Lewy body dementia cases, 711 proxy cases and 7624 controls with a

137 ests for identifying clinical Alzheimer-type dementia (CATD) are uncertain.

138 of drug treatment of clinical Alzheimer-type dementia (CATD) are uncertain.

139 osin-containing protein) was associated with dementia characterized neuropathologically by neuronal v

140 patients with stroke, cancer, heart failure, dementia, chronic obstructive pulmonary disease, and cir

141 Nursing home residents with dementia commonly experience low food intake, leading to

142 ecifically elevated in AD, but not in non-AD dementia compared with controls, whereas NfL was increas

143 est that protection from and pathogenesis of dementia depend upon combinatorial and opposite alterati

144 Dementia-diagnosed beneficiaries were more likely to hav

145 Compared with those without dementia diagnoses, beneficiaries with diagnosed dementi

146 on of Alzheimer's disease and frontotemporal dementia, diseases characterized by the accumulation of

147 arkers in participants with mild to moderate dementia due to Alzheimer's disease.

148 rticipants who developed Alzheimer's disease dementia during follow-up were compared with age and sex

149 clinicians to offer patients at low risk of dementia earlier reassurance and relieve pressures on sp

150 e BACE1-cleavage site protects from sporadic dementia, emphasizing APP's role in dementia pathogenesi

151 aring loss as an independent risk factor for dementia, estimated to account for 9% of cases.

152 of benzodiazepines or Z-drugs and subsequent dementia, even when exposures were cumulated or divided

153 uncil, Swedish Alzheimer Foundation, Swedish Dementia Foundation, Alzheimer Society Research Program.

154 ow-up were compared with age and sex-matched dementia-free control subjects.

155 1% female) to late life (1998), and then 744 dementia-free survivors were followed further into late

156 a p-tau181 distinguished Alzheimer's disease dementia from amyloid beta-negative young adults (AUC=99

157 burden and more accurately distinguishes AD dementia from non-AD neurodegenerative disorders.

158 precise relationship between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) i

159 c lateral sclerosis (ALS) and frontotemporal dementia (FTD) and lead to the production of aggregating

160 c lateral sclerosis (ALS) and frontotemporal dementia (FTD) are overlapping neurodegenerative disorde

161 c lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two related neurodegenerative disease

162 c lateral sclerosis (ALS) and frontotemporal dementia (FTD) as well as in the wild-type mice and tau

163 Frontotemporal dementia (FTD) is a common neurogenerative disorder char

164 c lateral sclerosis (ALS) and frontotemporal dementia (FTD) is a hexanucleotide repeat expansion in C

165 Frontotemporal dementia (FTD) is the second most prevalent form of pre-

166 Patients with frontotemporal dementia (FTD) resulting from granulin (GRN) haploinsuff

167 The frontotemporal dementia (FTD) spectrum of neurodegenerative disorders i

168 c lateral sclerosis (ALS) and frontotemporal dementia (FTD) susceptibility, and may underlie differen

169 n early pathological event in frontotemporal dementia (FTD), however biomarkers are lacking.

170 ophic lateral sclerosis (ALS)/Frontotemporal dementia (FTD), the (G4C2)-RNA repeat expansion from C9o

171 No treatment for frontotemporal dementia (FTD), the second most common type of early-ons

172 a with Lewy bodies (DLB), and frontotemporal dementia (FTD).

173 ophic lateral sclerosis (ALS)/frontotemporal dementia (FTD).

174 mplicated in familial ALS and frontotemporal dementia (FTD).

175 validated fluid biomarkers in frontotemporal dementia (FTD).

176 c lateral sclerosis (ALS) and frontotemporal dementia (FTD).

177 most common genetic cause of frontotemporal dementia (FTD).

178 ificantly associated with resident's gender, dementia, functional status, staffing level, or the leve

179 on in known amyotrophic lateral sclerosis or dementia genes.

180 ntia diagnoses, beneficiaries with diagnosed dementia had lower likelihood of seeing any eye care pro

181 Patients with iRBD who developed dementia had scores similar to clinical and prodromal pa

182 gh hypertension is a leading risk factor for dementia, how ischemic stroke contributes to this neurod

183 more prominent in individuals with vascular dementia (HR = 1.94, 95% CI = 1.84-2.04).

184 Including apathy in predictive models of dementia improved model fit.

185 can be used to assess the risk of developing dementia in a non-demented population.

186 MH) on MRI contributes to the development of dementia in Alzheimer's disease (AD), but it has not bee

187 hich they are associated with future risk of dementia in asymptomatic subjects is not clear.

188 variables works best for predicting risk of dementia in LMICs is needed.

189 ular risk factors increase the likelihood of dementia in older people but their impact on cognitive a

190 e, there was a slightly higher odds ratio of dementia in patients with the lowest use of benzodiazepi

191 ring associates with pathologies relevant to dementia in preclinical populations.

192 Baseline apathy scores predicted dementia in SCANS (HR 1.49, 95% CI 1.05 to 2.11, p=0.024

193 ot depression, may be a prodromal symptom of dementia in SVD, and may be useful in identifying at-ris

194 ed to both Parkinson's disease and Lewy body dementia; in particular, patients bearing the E46K disea

195 Dementia incidence until 2014 was obtained from national

196 Dementia incidence was assessed over 3-5 years, with dia

197 hat carefully measure cognitive function and dementia incidence.

198 ollow-up of 10-11 years for AD and all-cause dementia incidence.

199 We determined incident dementia including Alzheimer's disease and vascular deme

200 years follow-up, 549 participants developed dementia, including 374 cases with Alzheimer's disease d

201 likely pathogenic contributor to age-related dementia, including Alzheimer's disease, inextricably li

202 participating in the Genetic Frontotemporal dementia Initiative (GENFI), all of whom had at least on

203 ere obtained from the Genetic Frontotemporal Dementia Initiative.

204 he appropriate genetic test in most cases of dementia is a next-generation sequencing gene panel, tho

205 Dementia is a rapidly rising global health crisis that s

206 , the second most common type of early-onset dementia, is available, but therapeutics are being inves

207 associated with a lower risk of Alzheimer's dementia, it is not yet known whether APOE2 homozygotes

208 the arteries (atherosclerosis) was linked to dementia long ago, but subsequently, Alzheimer's plaques

209 ed to amyloid-associated diseases, including dementia, macular degeneration, and diabetes mellitus, i

210 People living with dementia may call out repetitively, sometimes called dis

211 ears of follow-up, 462 individuals developed dementia (mean age at baseline = 57.5 +/- 5.9 years, 58%

212 cbi)) or motor neuron disease-frontotemporal dementia (MND-FTD).

213 amyotrophic lateral sclerosis/frontotemporal dementia/myopathy, respectively.

214 ly impaired (MCI n = 67, Alzheimer's disease dementia n = 21), data accessed October 2018]; and Trans

215 ly impaired (MCI n = 16, Alzheimer's disease dementia n = 26), data obtained November 2017 to January

216 = 1), and behavioral-variant frontotemporal dementia (n = 1).

217 ients), 11 of mixed disease (n = 8119), 4 of dementia (n = 1036), and 3 of chronic obstructive pulmon

218 s who later converted to Alzheimer's disease dementia (n = 40) had accelerated p-tau217 compared to o

219 em clinical diagnoses were Alzheimer disease dementia (n = 6), probable dementia with Lewy bodies (n

220 123), other types of dementia (n.

221 history of PD, a positive family history of dementia, non-smoking, low alcohol consumption, depressi

222 ighest use had the lowest odds of developing dementia (odds ratio=0.83, 95% CI=0.77, 0.88).

223 ot between atherosclerosis and subsequent AD dementia or AD pathology.

224 nificantly associated with a reduced risk of dementia or cognitive impairment (12 trials; 92 135 part

225 tly associated with a lower risk of incident dementia or cognitive impairment.

226 >=30 mg/g were not associated with probable dementia or MCI, nor did the urinary ACR modify the effe

227 e eGFR <60 ml/min per 1.73 m(2) and risk for dementia or MCI.

228 le risk factors for bleeding), patients with dementia or those living in a long-term care home, patie

229 ants), of which 12 reported the incidence of dementia (or composite of dementia and cognitive impairm

230 remained cognitively stable, converted to AD dementia, or converted to non-AD dementias, and in cogni

231 al," was a composite of all-cause mortality, dementia, or persistent physical disability.

232 otrophic lateral sclerosis or frontotemporal dementia, or to slow progression.

233 18 month follow up period and conversion to dementia over a 5.5 year period.

234 etrics had a significantly increased risk of dementia (p = 0.031).

235 ar or cerebrovascular disease (P = 0.94) and dementia (P = 0.77), prevalence of diabetes mellitus (P

236 We applied a validated NGS dementia panel to 3241 patients with dementia and health

237 , Abeta-independent pathway that facilitates dementia pathogenesis in humans.

238 sporadic dementia, emphasizing APP's role in dementia pathogenesis.

239 om a C9orf72-HRE positive ALS/frontotemporal dementia patient using CRISPR/Cas9 genome editing and ho

240 Approximately 10% of dementia patients have idiopathic normal pressure hydroc

241 biomarkers in mild cognitive impairment and dementia patients.

242 developing his mature concept of hebephrenic dementia praecox (DP) in his 4th (1893) through 6th text

243 ndrome to fit into his emerging construct of dementia praecox.

244 This study investigated whether dementia prediction models developed in HICs are applica

245 To date, dementia prediction models have been exclusively develop

246 Patients with Lewy body dementia present with a wide range of cognitive, neurops

247 ghlight the need for early interventions for dementia prevention to mitigate the effect of APOE epsil

248 ts (aged 40-59 at baseline) from the PREVENT-Dementia programme underwent MRI scans on two separate o

249 ies, multiple system atrophy, frontotemporal dementia, progressive supranuclear palsy, corticobasal s

250 c & Lipid Disorders, Neurovascular Disease & Dementia, Promoting Health & Prevention, Rhythm Disorder

251 astrocytic injury/activation or induction of dementia-related brain pathologies by the infection.

252 As ageing is the main risk factor for dementia-related neurodegeneration, changes in the timin

253 vidence, the pathways linking depression and dementia remain unclear.

254 der adults putatively at-risk for developing dementia- remitted depression (MDD), non-amnestic MCI (n

255 For the purposes of this study, the 10/66 Dementia Research Group follow-up wave information from

256 e) was significantly associated with a lower dementia risk (HR range: 0.03 to 0.26; p < 0.05), wherea

257 otential therapeutic opportunities to reduce dementia risk, including early and effective use of anti

258 higher gamma-GT quartile had more increased dementia risk.

259 ing contributions of the latter to late life dementia risk.

260 the right temporal variant of frontotemporal dementia (rtvFTD) is still equivocal.

261 europsychological investigations of semantic dementia (SD).

262 ne in the sum of boxes score from the CDR(R) Dementia Staging Instrument and in five cognitive domain

263 was formulated: screening for Alzheimer-type dementia starting at age 40 years.

264 Data from 378 participants in the PREVENT Dementia Study aged 40-59 years.

265 adults with DS, prior to the development of dementia symptoms.

266 We studied patients with semantic dementia-the paradigmatic disorder of the brain system m

267 s, Alzheimer's disease, and diabetes-induced dementia, there are no disease-modifying therapies that

268 ium is associated with cognitive decline and dementia, there is limited evidence to support causality

269 Nearly all donors had dementia; three (two pure LATE-NC and one pure ADNC) don

270 association between blood pressure (BP) and dementia traits.

271 ]; and Translational Biomarkers in Aging and Dementia [TRIAD, n = 116; 74 cognitively unimpaired, 42

272 ity of 0.89 (95% CI, 0.85 to 0.93) to detect dementia using a cutoff of 23 or less or 24 or less (15

273 al hypoperfusion is associated with vascular dementia (VaD).

274 nsidered as a separate disease from vascular dementia (VAD).

275 ar contributions to cognitive impairment and dementia (VCID), particularly in women.

276 plasma P-tau217 in cohort 2 for clinical AD dementia vs other neurodegenerative diseases (AUC, 0.96

277 life and late life, the fully adjusted HR of dementia was 0.25 (95% CI: 0.08, 0.86; p = 0.028) for pe

278 The fully adjusted hazard ratio (HR) of dementia was 0.71 (95% confidence interval [CI]: 0.43, 1

279 Dementia was ascertained through 2013 using cognitive ex

280 During the follow-up examinations, dementia was diagnosed in 61 persons in 1998 and additio

281 Dementia was identified from diagnosis codes documented

282 Dementia was identified from diagnosis codes on or prior

283 International Consortium for Frontotemporal Dementia was recently established to determine the curre

284 Community older adults without stroke or dementia were recruited (n = 515).

285 , or benefitting little from self-care (e.g. dementia) were excluded.

286 , and damaged blood vessels in multi-infarct dementia when compared to AD.

287 ase (sCJD) presents as a rapidly progressive dementia which is usually fatal within six months.

288 associated with a higher risk of Alzheimer's dementia, while the APOE2 allele is associated with a lo

289 ditions, including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atro

290 disorders, including Alzheimer disease (AD), dementia with Lewy bodies (DLB), and frontotemporal deme

291 sease, Parkinson's disease with dementia and dementia with Lewy bodies (DLB), are human neurodegenera

292 n = 38), Parkinson disease (PD, n = 16), and dementia with Lewy bodies (DLB, n = 13), and CON subject

293 ixed Alzheimer disease dementia and probable dementia with Lewy bodies (n = 1), Parkinson disease wit

294 Alzheimer disease dementia (n = 6), probable dementia with Lewy bodies (n = 12), mixed Alzheimer dise

295 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K-SNCA mutation ca

296 n known to aggregate in Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

297 p behavioural disorder, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, fron

298 tion of tau mutants linked to frontotemporal dementia with parkinsonism and alpha-synuclein by increa

299 Globally, 50 million people live with dementia, with Alzheimer disease (AD) being responsible

300 rogeneity in Alzheimer's disease and related dementias, with a principal focus on neuroimaging studie